Abstract:Ovarian cancer is a gynecologic malignancy with high mortality. The main reason is that it is detected at an advanced stage due to a lack of early diagnosis and treatment. Therefore, it is of great interest to develop a chemical tool that can visualize ovarian cancer cells in real-time and eliminate them. Unfortunately, probes that can simultaneously monitor both modes of action for the diagnosis and treatment of ovarian cancer have not been developed. Here, we designed a novel prodrug fluorescent probe ( YW-OAc ) that not only visually tracks cancer cells but also enables the on-demand delivery of chemotherapeutic agents. By β -Gal-mediated glycosidic bond hydrolysis, the fluorescent signal changed from blue to green (signal 1), enabling visual tracking of ovarian cancer cells. Subsequently, the identified cancer cells were subjected to precise light irradiation to induce anticancer drug release accompanied by a fluorescence transition from green to blue (signal 2), enabling real-time information on drug release. Thus, the prodrug fluorescent probe YW-OAc provides comprehensive two-step monitoring during cancer cell recognition and clearance. Notably, YW-OAc exhibited high affinity ( K m = 3.74 μM), high selectivity, and low detection limit for β -Gal (0.0035 U/mL). We also demonstrated that YW-OAc can visually trace endogenous β -Gal in different cells and exhibit high phototoxicity in ovarian cancer cells. We hope that the prodrug fluorescent probe YW-OAc , can be used as an effective tool for biomedical diagnosis and treatment.

An Enzyme-Activatable Probe Liberating AIEgens: On-Site Sensing and Long-Term Tracking of Β-Galactosidase in Ovarian Cancer Cells

β-Galactosidase-Activated near-infrared AIEgen for ovarian cancer imaging in vivo

First aggregation-induced emission-active probe for species-specific detection of β-galactosidase

Debut of a NIR ESIPT-based fluorescent probe with synergistic effects for boosting high-contrast imaging of β-galactosidase in ovarian cancer

Design strategies and biological applications of β-galactosidase fluorescent sensor in ovarian cancer research and beyond

β-galactosidase instructed in situ self-assembly fluorogenic probe for prolonged and accurate imaging of ovarian tumor

Enzyme‐Mediated Intracellular Polymerization of AIEgens for Light‐Up Tumor Localization and Theranostics

Biosensors for the Detection of Enzymes Based on Aggregation-Induced Emission

An NIR Fluorescence Turn-on and MRl Bimodal Probe for Concurrent Real-time in vivo Sensing and Labeling of β-Galactosidase

A Chalcone-based ESIPT and AIE Fluorophore for β-galactosidase Imaging in Living Cells

A unimolecular theranostic system with H2O2-specific response and AIE-activity for doxorubicin releasing and real-time tracking in living cells

Design and application of prodrug fluorescent probes for the detection of ovarian cancer cells and release of anticancer drug

A Cascade Enzymatic Reaction Activatable Gemcitabine Prodrug with an AIE-based Intracellular Light-Up Apoptotic Probe for in Situ Self-Therapeutic Monitoring

Cascade-Activated AIEgen-Peptide Probe for Noninvasively Monitoring Chymotrypsin-like Activity of Proteasomes in Cancer Cells

Visualized Enzyme-Activated Fluorescence Probe for Accurately Detecting β-Gal in Living Cells and BALB/c Nude Mice

Cleancap-Regulated Aggregation-Induced Emission Strategy for Highly Specific Analysis of Enzyme.

[Antimycotic action in vitro of sodium ethyl thiosalicylate and of mercury on certain strains of Candida albicans].

Design and Synthesis of Lanthanide(III) Complex Based Luminescence Probes for Time-Resolved Luminescence Detection of β-Galactosidase

Spatially Engineered Janus Hybrid Nanozyme Toward SERS Liquid Biopsy at Nano/Microscales

A novel "AIE + ESIPT" near-infrared nanoprobe for the imaging of γ-glutamyl transpeptidase in living cells and the application in precision medicine.

A Fluorescent Light-Up Probe Based on AIE and ESIPT Processes for Β-Galactosidase Activity Detection and Visualization in Living Cells.